STAT3 and cancer: Attractive therapeutic targets include: the modulation of nitric oxide54,107, histone deacetylase inhibitors169, YAP and TAZ156, inhibition of VEGFR2/MET/RET by cabozantinib in MPNST102, the HIPPO pathway152,155 and Ral-GEFs for MPNSTs119,170, CRMP-2 for therapeutic intervention in patients with NF1 pain171, ALK172, inhibition of FAF272 and STAT3 on neurofibromas173, and VCP174 for NF1-cancer therapy, 5-HT6 receptor for cognitive impairment175 and neurofibromin-mediated cAMP production176.